Enfortumab Vedotin-Induced Diabetic Ketoacidosis and Acute Tubulointerstitial Nephritis Requiring Intensive Care in the Treatment of Advanced Urothelial Carcinoma: A Case Report
Case Reports in Oncology · 29.04.2025 · 18 (1) · 667-674
DOI: 10.1159/000545957 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 29.04.2025. Verfasst von Ryo Matsui und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Intensivpflege
Abstract (Originalsprache)
Introduction
Enfortumab vedotin (EV) has been approved for the treatment of many types of cancer, and its use is still expanding. It is an essential drug used as a standard treatment for advanced and metastatic urothelial carcinoma but is known to cause various adverse events (AEs). Case Presentation: We report a patient with metastatic urothelial carcinoma who experienced multiple AEs associated with diabetic ketoacidosis (DKA) during EV treatment. The onset of DKA during EV treatment has been reported to be associated with poor prognosis. Although strict management was required in the intensive care unit, we were able to save the patient’s life.
Conclusion
Although the detailed mechanism that induced insulin resistance remains unclear, the patient required high-dose insulin because of a marked increase in insulin resistance. If hyperglycemia is observed during EV therapy, DKA may lead to the occurrence of serious AEs. We report on the pathogenesis and management of drug-induced DKA caused by EV based on our case and a literature review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Diabetes, Metabolism and Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Zitieren
APA
Matsui, R., Kawasaki, Y., Satake, Y., Takahashi, K., Kurosawa, S., Sato, T., Katayama, H., Sato, T., Kawamorita, N., Yamashita, S., Katagiri, H., & Ito, A. (2025). Enfortumab Vedotin-Induced Diabetic Ketoacidosis and Acute Tubulointerstitial Nephritis Requiring Intensive Care in the Treatment of Advanced Urothelial Carcinoma: A Case Report. Case Reports in Oncology, 18(1), 667-674. https://doi.org/10.1159/000545957
Vancouver
Matsui R, Kawasaki Y, Satake Y, Takahashi K, Kurosawa S, Sato T, et al. Enfortumab Vedotin-Induced Diabetic Ketoacidosis and Acute Tubulointerstitial Nephritis Requiring Intensive Care in the Treatment of Advanced Urothelial Carcinoma: A Case Report. Case Reports in Oncology. 2025;18(1):667-674. doi:10.1159/000545957
BibTeX
@article{Matsui2025,
author = {Matsui, Ryo and Kawasaki, Yoshihide and Satake, Yohei and Takahashi, Kei and Kurosawa, Satoko and Sato, Tomonori and Katayama, Hiromichi and Sato, Takuma and Kawamorita, Naoki and Yamashita, Shinichi and Katagiri, Hideki and Ito, Akihiro},
title = {Enfortumab Vedotin-Induced Diabetic Ketoacidosis and Acute Tubulointerstitial Nephritis Requiring Intensive Care in the Treatment of Advanced Urothelial Carcinoma: A Case Report},
journal = {Case Reports in Oncology},
year = {2025},
volume = {18},
number = {1},
pages = {667--674},
doi = {10.1159/000545957}
}
EUVIMED